Logo image
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
Journal article   Open access   Peer reviewed

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial

Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, Valeriy Breder, Dariusz M. Kowalski, Theodore Pollock, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, …
JAMA oncology, v 7(9)
01 Sep 2021
PMID: 34086039
url
https://doi.org/10.1001/jamaoncol.2021.2301View
Published, Version of Record (VoR) Open

Abstract

Comments Online First Original Investigation ESI Highly Cited Paper (Incites)
This nonrandomized trial evaluates the treatment outcomes and safety of pembrolizumab plus concurrent chemoradiation therapy in stage III non–small cell lung cancer.

Metrics

13 Record Views
204 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Highly Cited Paper 
Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Oncology
Logo image